Background: Despite potential adverse-events in a paediatric population, corticos-
| INTRODUCTION
Crohn's disease (CD) is a chronic illness characterised by destructive transmural inflammation of the gastrointestinal tract with periods of flares and remission. 1 While CD is most commonly diagnosed among 15-35 year olds, a quarter of patients are diagnosed as children under the age of 18. 2, 3 Corticosteroids are the most commonly used medication to induce remission in the USA, 4 but can pose particular risks in a paediatric population including: growth retardation, low bone mineral density, adrenal suppression and body image dissatisfaction. 5 As an alternative, gastroenterologists sometimes elect to use exclusive enteral nutrition (EEN) as induction therapy in these patients 6 because adverse effects of enteral nutrition are generally limited to gastrointestinal tolerability (eg, nausea, vomiting, diarrhoea) though rare reports of refeeding syndrome exist. 7 This therapy is frequently used in Europe, but fewer than 4% of paediatric gastroenterologists use it in North America, though emerging data shows it is gaining more prominence in Canada. 6, 8 The benefits of enteral nutrition in patients with Crohn's disease were auspiciously identified in the surgical literature when patients administered enteral nutrition to optimise their nutritional status pre-operatively, improved unexpectedly, with some even avoiding the intended surgery. 9 The mechanism of the beneficial effects of enteral nutrition was hypothesised to be the avoidance of enteral antigens resulting in improvements in intestinal permeability, though recent studies have elucidated other possibilities, 10 including down regulation of pro-inflammatory cytokines. 11 Others have found beneficial changes to the gut microbiome among Crohn's patients treated with enteral nutrition. 12, 13 There are three major categories of enteral nutrition formulas, and they are differentiated by the structure of their protein content.
Elemental diets contain no intact protein, only amino acids. Unfortunately, elemental diets are distinctly distasteful and often require a feeding tube to administer. Even semi-elemental diets (ie, peptides of varying length) were found to be intolerable with 57% of patients withdrawing from a major study mostly due to poor palatability. 14 Polymeric diets (ie, intact protein), which are more palatable and do not always require feeding tube placement for administration, have been shown to perform as well as elemental and semi-elemental diets in the induction of remission of CD. 15 Previous comparisons regarding the effectiveness of EEN vs CS in remission induction have yielded mixed results. Five of seven meta-analyses published over the last 20 years have found CS to be superior to EEN at inducing remission. [15] [16] [17] [18] [19] Of the seven meta-analyses, two have mixed populations of adults and children, three included only adult studies and two focused only on children. EEN is hypothesised to work more effectively in children than adults, though the reasons for this are unclear. 6 The two paediatric metaanalyses focused only on induction of remission, 20, 21 found no difference in remission induction comparing CS to EEN.
In the 10 years that have elapsed since the most recent metaanalysis on this subject, several more studies, [22] [23] [24] [25] [26] 
| Types of participants
Patients under the age of 18 with newly diagnosed or relapsed active Crohn's disease.
| Types of interventions
Administration of EEN in the following formulations: polymeric formula, semi-elemental formula, or elemental formula to one group of patients and CS to the comparator arm were reviewed for the specific outcomes described in this systematic review and meta-analysis. Patients in the EEN arm must not be receiving any other medication, and those receiving CS must only be treated with CS. Although there has been no convincing evidence that there is any difference in benefit between the types of formulas used, and the Zachos et al. 15 Cochrane analysis combined all exclusive enteral nutrition analyses, we conducted both combined and stratified analyses.
| Exclusion criteria
Trials without an EEN arm and trials without at least one clearly defined CS comparator arm were excluded from this analysis. In addition, authors who did not define remission within the text of their manuscript were excluded.
| Types of outcome measures
All of the potential studies that met inclusion criteria ( Figure 1 ) measured disease activity with either the lloyd-still index (LSI) or paediatric Crohn's disease activity index (PCDAI). Because the cut-off points for each scale is subjective, we defined our outcome variable as the percentage of patients who remained in remission, as defined by the study authors. In cases where this information was not provided in the published manuscript, the additional information was sought directly from the authors. 
| Search methods for identification of studies
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| Quality assessment
Three authors (SLF, AF, AS) independently reviewed the quality of the studies. We evaluated the bias in observational studies using the New Castle-Ottawa scale 32 and randomised controlled trials using the Cochrane RoB tool. 33 Observational studies, less rigorous than randomised controlled trials (RCT), inherently introduced uncertainty and heterogeneity into our meta-analysis. As such, we conducted two sensitivity analyses. First, we removed the study where the author admitted that the study team preferentially assigned patients to the enteral nutrition arm of the trial (Lambert et al. 24 ). Second, we analysed the results for the RCTs, prospective cohort studies, and retrospective cohort studies separately to determine if the results from the non-RCTs affected our heterogeneity calculation or produced a different result from the more robust RCTs. Because there was not a heterogenous effect across strata when we examined each study type separately for our main outcome, we felt it was appropriate to combine study types as hypothesis generating rather than confirmatory analyses.
| Data extraction
Data extraction forms were developed by two of the authors (AF, AS) and confirmed by a third (SLF). Data were extracted jointly by two authors (AF, AS) and then a third author (SLF) independently extracted the data. Disagreements were reconciled by discussion.
Extracted data included: participant age and disease characteristics, number of patients in each treatment arm, outcome measurement (PCDAI vs LSI vs "biochemical remission"), study design, study inclusion criteria, details of enteral nutrition formulation and intervention, details of medical intervention, length of follow-up and remission rates at the follow-up visit.
| Statistical analyses
The percentages of patients in remission at the end of the first follow-up period from each study were pooled. Cross-study variation due either to heterogeneity or chance was quantified using both I 2 and Chi² where P < .10 or I 2 > 50% indicates substantial heterogeneity. Fixed-effect models were used. If heterogeneity was present, a random effects model was used to calculate the most conservative confidence intervals. Each study's weight was determined using Mantel-Haenszel methods. All analyses were conducted using RevMan5 (version 5.3.5, Copenhagen, Denmark).
3 | RESULTS
| Risk of bias in included studies
We evaluated bias in randomised controlled trials according to the methods described in the Cochrane Handbook, 33 which includes consideration of the following: blinding, randomisation, completeness Table 3 for bias analysis of observational studies according to the New Castle-Ottawa scale.
of outcome data and method of reporting data (Table 1) . Observational studies were evaluated for bias using the New Castle-Ottawa tool 32 (Table 3) . Data have been reported according to MOOSE guidelines (see Appendix 1). 34 
| Characteristics of included studies
Of the nine trials that met our inclusion criteria (Table 1 , Figure 1 ), eight study authors either included or provided the proportion of patients who entered remission in each arm which could be pooled in the meta-analyses.
Of the eight trials included in the quantitative meta-analysis, seven compared EEN to CS (Borreli et al., 26 Berni Canani et al., 35 Hojsak et al., 22 Kierkus et al., 23 Lambert et al. 24 Levine et al., 25 Luo et al. 36 ). Sanderson et al. 29 compared EEN to sulfasalazine + CS.
Five studies used a polymeric diet. Sanderson et al. 29 used an elemental diet, and Berni Canani et al. 35 had separate arms for elemental, semi elemental and polymeric diets that were pooled together for our meta-analysis. Luo et al. 36 did not specify the type of enteral nutrition that they used.
Three studies provided specific details about the steroid dosing arms. Berni Canani et al. 35 The study participants in all trials included in the meta-analysis were children, and the diets were administered via nasogastric tube (elemental diets) or orally. Of the eight studies, four studies (Lambert, 24 Levine, 25 Borrelli, 26 Luo 36 ) included only newly diagnosed patients, whereas the others included both newly diagnosed and relapsed patients, or relapsed only. Disease activity and remission were based on PCDAI scores, though the cutoff for remission varied and some studies did include supplemental information from biomarkers or endoscopic scores (CDEIS). Sanderson et al. 29 used the LSI along with biomarkers (CRP, ESR, albumin concentration) to determine remission. Correspondence with the author was required to obtain patient level Lloyd Still scores levels at multiple time points. Outcomes were assessed at 6-8 weeks except Borrelli et al. 26 assessed outcomes after 10 weeks of treatment.
One other paper met inclusion criteria, but was not included in the meta-analysis because data could not be abstracted from the paper and could not be obtained from the corresponding author.
Papadopoulous et al. 30 used an elemental diet arm (n = 19) and oral prednisone (2 mg/kg/d, max 60 mg/d; n = 17) with taper over 8 weeks, but did not provide individual patient status at end of induction. Instead they describe successful treatment of flare episodes (each patient could have more than one episode of flare).
They found remission in 83% of episodes treated with EEN and 64% treated with prednisone. Figure 2 ). Heterogeneity was not demonstrated
Given the interest in possible treatment differences between newly diagnosed CD patients and those with relapsed disease, the studies were separately analysed by type of patient. Borrelli et al., 26 Lambert et al., 24 Levine et al. 25 and Lou et al. 36 included only newly diagnosed patients. Although these studies were an RCT, two retrospective cohort studies and a prospective cohort study, respectively, we combined them to do an exploratory analysis. Figure 3B ). There was no statistically significant difference in remission odds distinguishing newly diagnosed patients and relapsed patients, though the trend was towards EEN being more effective in those who were newly diagnosed as opposed to relapsed patients. Heterogeneity was not demonstrated (I 2 = 1%).
| Benefit of enteral nutrition therapy beyond end of induction
An exploratory subanalysis of two studies (Sanderson et al., 29 Berni
Canani et al. 35 ) was performed to ascertain if being induced into remission with EEN vs CS had led to a more durable remission.
Although Sanderson et al. 29 was an RCT and Berni Canani et al. 
| Polymeric formula and elemental formula for remission induction
The majority of the included studies (Hojsak et al., 22 Kierkas et al., 23 Lambert et al., 24 Levine et al., 25 and Borrelli et al. 26 ), used a polymeric formula in their enteral nutrition arm. When we compared Figure 5 ). Sanderson et al. 29 was the only study which used an elemental diet only arm and Lou et al. 36 did not specify the type of formula used in their study.
| Mucosal healing
Borrelli et al. 26 and Berni Canani et al. 35 provided mucosal healing data at the end of induction. Although these were two different types of studies-an RCT and a retrospective cohort study, we conducted a hypothesis generating analysis to determine whether mucosal healing rates were higher among patients who received EEN compared to those who received CS. 
| Effect of EEN vs CS on CRP normalisation
Hojsak et al., 22 Levine et al., 25 and Sanderson et al. 29 Test for overall effect: Z = .55 (P = .58) Figure 6B ). Again, heterogeneity was not demonstrated (I 2 = 0%).
| DISCUSSION
Our systematic review and meta-analysis of induction regimens in children with Crohn's disease, did not find a treatment benefit of corticosteroids over exclusive enteral nutrition. This finding held true in the subanalysis of newly diagnosed patients. In our hypothesis generating analysis, EEN also had superior mucosal healing odds (P<.05), suggesting that this is an end point to be explored in future trials. There is also a possibility that the benefits of induction with enteral nutrition are more durable than induction with corticosteroids, but this finding is driven by one study, Berni Canani et al. 35 In fact, the two studies combined to study this question may not reflect current practice, namely using steroids or mesalamines as post-induction maintenance regimen in Crohn's disease. 29, 35 Our findings are in contrast with the most recent Cochrane review on the subject 15 which found corticosteroids superior to enteral nutrition (OR 0.33). This is potentially explained by the fact that we only used high-quality studies. When the Cochrane authors restricted their analysis to only high-quality studies, they also found no difference between CS and EEN. Another potential explanation for their contrary findings is that they combined data from studies of both adults and children. Of the seven studies (n = 352) they pooled, only one study (n = 37, Borrelli et al.
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) was composed of paediatric patients. Given the heterogeneity of the results when stratifying by population age, it would seem reasonable to avoid combining paediatric and adult data in future analyses as it may result in underestimating the benefit of enteral nutrition in the paediatric population. Some physicians believe that the discordance in efficacy between adults and children is overstated. In clinical situations where tolerability of the EN product is high, enteral nutrition can induce remission in adult populations, suggesting that improved tolerability should be an area of further research.
Two previous meta-analyses and two systematic reviews on the subject of treatments for induction of remission in children with
Crohn's disease have been performed, and our results confirmed their findings. Heuschkel et al. 21 (n = 194), concluded that there was no difference in efficacy between enteral nutrition and corticosteroids to treat active Crohn's disease. However, this study was underpowered (n = 144) to identify differences less than/equal 20% between the steroid and EEN groups. 6 Of the seven studies combined in their meta-analysis four did not meet our inclusion criteria.
Two studies 38, 39 have only ever been published as abstracts, and
have not undergone detailed peer-review. It is not clear whether patients overlapped between the two studies by the same author and the decision to avoid including in their meta-analysis was shared by the Cochrane review group. 15 Thomas et al., 39 was excluded from our analysis because their outcome was "improvement," rather than remission. Another, Breese et al., 40 included eight different steroid dosing strategies (prednisone 5 mg/d -40 mg/d) among 10 patients treated with corticosteroids. The heterogeneous patient populations and an inability to evaluate details of trial mechanics, made outcomes for more than 50% of the included population impossible to
assess.
An earlier meta-analysis, Dziechciarz et al. 20 (n = 204), also suggested similar efficacy between EN and CS for treating active
Crohn's disease in children. Their meta-analysis combined 4 studies.
Three of these studies did not meet our inclusion criteria. Like
Heuschkel et al., 21 Dziechciarz et al. 20 also included the same two abstracts from Seidman et al. 37, 38 as previously described. Terrin et al. 2 was published in an Italian journal with an English abstract and non-English manuscript. As the full manuscript was not in English, we excluded it from our meta-analysis.
Recently, Pegnani et al. 41 conducted a large systematic review of paediatric nutrition and CD with several end points, including the efficacy of enteral nutrition on the induction of remission in a paediatric population. While they did not conduct a meta-analysis themselves, using evidence from Heuschkel et al. 21 and Dziechciarz et al., 20 they concluded that enteral nutrition in a paediatric population can effectively induce remission. However, they included Thomas et al. 39 and Terrin et al., 2 which we excluded for the reasons listed in the previous paragraph. They also included Ruuska et al., 42 Grover et al., 43 and Soo et al., 44 which we excluded because the former two articles did not use remission as their primary end point and the latter one did not have an enteral nutrition only arm.
Day et al. 45 also conducted a broad-view systematic review without meta-analysis on enteral nutrition in the treatment of paediatric Crohn's disease with several end points. While they also found that enteral nutrition can induce remission, they included the Seidman et al. abstracts, 37,38 the Thomas et al. 39 paper and the Terrin et al. 2 papers that we excluded for previously explained reasons.
While both of these systematic reviews contribute substantially to the understanding of paediatric CD and enteral nutrition, they were both broad in scope. Because we took a narrower viewpoint and only looked at enteral nutrition and its ability to affect remission induction, we were able to more completely examine the topic.
The goal of every meta-analysis is to include the best possible data and pool data from comparable patient populations. Our rigorous inclusion criteria disallowed the majority of studies included in two previous meta-analyses. Our meta-analysis included data from randomised controlled trials, prospective cohorts and retrospective cohort studies. Our systematic sensitivity analysis showed that when we stratified our results by study design, there was no difference across strata, meaning that the results from the prospective studies were similar to those from the retrospective studies and the RCTs.
By not including abstracts, we may have introduced publication bias into our study, but by only including full manuscripts, we were able to more fully assess the limitations of each study and understand sources of bias in assignment of EEN vs CS. We have detailed these biases in Table 1 . Moreover, we had no heterogeneity in the majority of our analyses, making our findings robust. A limitation to our systematic review is that the primary outcome for most included SWAMINATH ET AL.
| 653 studies was clinical remission, which is measured by PCDAI, a scale considered to be a fallible measure for evaluating response to therapy. As such, we included the previously unexplored end point of mucosal healing, a more robust measure of therapy response.
Another limitation to any research involving exclusive enteral nutrition is, of course, the different dietary cheats allowed and the difficulty in measuring the amount of nonformula nutrition ingested by participants. However, we believe this error to be random, and therefore would bias our results towards the null. A final potential limitation to our paper is that we chose our statistical models based on heterogeneity, while current Cochrane guidelines warrant choosing a model a priori and then using an alternative test as a sensitivity analysis.
Current clinical guidelines, from both the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition and its European counterpart, consider enteral nutrition acceptable to use in all patients with Crohn's disease. 46, 47 In fact, the European Society for Clinical Nutrition and Metabolism guidelines recommend EN as a first line therapy for children and adolescents with CD, with "strong consensus". 47 However, there are many persistent unanswered questions on this subject. Specifically, the mechanism of action of enteral nutrition remains vague and there is still little guidance on which types of patients would be most likely to benefit, though weak evidence suggests effectiveness is greater with small bowel involvement. 7 With regard to disease duration, our analysis suggests that outcomes may differ between newly diagnosed and previously diagnosed patients. Future guidelines may need to make that distinction when it comes to benefits of induction with these therapies. 46 Challenges also remain in considering induction treatment duration and the best strategy to maintain remission as long-term exclusive enteral nutrition is unlikely to be acceptable to most patients.
In summary, our study suggests that exclusive enteral nutrition works equally as well as corticosteroids in inducing remission in paediatric Crohn's disease based on clinical symptom scores, but EEN could potentially be superior when assessing improvement by mucosal healing end points. We believe these results suggest a need for further research in this area. EEN may have the added benefit of minimising growth failure, avoiding undesirable and difficult to reverse changes to body habitus, and can potentially result in a deeper and longer duration of remission. As such, greater advocacy for this therapy among physicians from the USA may be warranted.
